The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial (2013)
- Autores:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- Assuntos: MEDICAMENTO; ANTICOAGULANTES; SÍNDROME CORONARIANA AGUDA
- Idioma: Inglês
- Imprenta:
- Fonte:
- Título do periódico: Circulation
- ISSN: 0009-7322
- Volume/Número/Paginação/Ano: v. 128, n. 22, abst. 11382, 2013
- Nome do evento: American Heart Associations of the Scientific Sessions and Resuscitation Science Symposium
-
ABNT
O'DONOGHUE, Michelle L. et al. The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial. Circulation. Dallas: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A11382?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4. Acesso em: 26 abr. 2024. , 2013 -
APA
O'Donoghue, M. L., Mega, J. L., Braunwald, E., Nicolau, J. C., Bhatt, D. L., Murphy, S. A., & Gibson, C. M. (2013). The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial. Circulation. Dallas: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A11382?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4 -
NLM
O'Donoghue ML, Mega JL, Braunwald E, Nicolau JC, Bhatt DL, Murphy SA, Gibson CM. The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial [Internet]. Circulation. 2013 ; 128( 22):[citado 2024 abr. 26 ] Available from: http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A11382?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4 -
Vancouver
O'Donoghue ML, Mega JL, Braunwald E, Nicolau JC, Bhatt DL, Murphy SA, Gibson CM. The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial [Internet]. Circulation. 2013 ; 128( 22):[citado 2024 abr. 26 ] Available from: http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A11382?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Como citar
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
